Compare LGND & LEU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGND | LEU |
|---|---|---|
| Founded | 1987 | 1998 |
| Country | United States | United States |
| Employees | 68 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Mining & Quarrying of Nonmetallic Minerals (No Fuels) |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.0B |
| IPO Year | N/A | 1998 |
| Metric | LGND | LEU |
|---|---|---|
| Price | $234.02 | $206.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 12 |
| Target Price | $247.29 | ★ $255.55 |
| AVG Volume (30 Days) | 179.9K | ★ 840.1K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.90 |
| Revenue | N/A | ★ $193,000,000.00 |
| Revenue This Year | $1.25 | $3.76 |
| Revenue Next Year | $19.41 | $6.04 |
| P/E Ratio | $76.27 | ★ $57.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $98.90 | $66.38 |
| 52 Week High | $247.38 | $464.00 |
| Indicator | LGND | LEU |
|---|---|---|
| Relative Strength Index (RSI) | 60.36 | 52.12 |
| Support Level | $180.85 | $187.95 |
| Resistance Level | N/A | $219.85 |
| Average True Range (ATR) | 10.11 | 13.80 |
| MACD | 1.34 | 3.23 |
| Stochastic Oscillator | 67.93 | 52.55 |
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.